<DOC>
	<DOCNO>NCT00258557</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety tolerability TMC114/r versus Kaletra ( combination pill lopinavir ritonavir , ( `` lpv/rtv '' ) HIV-1 infected patient never treat anti-retroviral medication ( refer `` treatment-naïve '' patient ) .</brief_summary>
	<brief_title>TMC114-C211 : Trial Investigational Protease Inhibitor TMC114 With Ritonavir ( `` TMC114/r '' ) HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications .</brief_title>
	<detailed_description>This randomize , control , open-label trial investigate antiviral activity , tolerability safety TMC114/r ) versus lpv/rtv treatment-naive HIV-1 infected patient . Six hundred sixty treatment-naïve HIV-1 infect patient randomize 1:1 ratio either 800/100 mg TMC114/r daily , total daily dose 800/200 mg lpv/rtv . All patient take TMC114/r lpv/rtv combination NRTI background Truvada ( combination pill tenofovir emtricitabine , `` TDF/FTC '' ) . The trial consist screen period approximately 14 28 day 96-week treatment period , follow 4-week follow-up period . The anti HIV-1 therapy initiate baseline change end treatment period . After end treatment period ( maximum 96 week ) , patient follow additional 4 week follow-up adverse event laboratory abnormality resolution . Patients fail either virologically due intolerance TMC114/r lpv/rtv therapy , judge investigator , meet one withdrawal criterion withdraw trial may opportunity participate rollover phase trial . The primary efficacy parameter virologic response define confirmed viral load &lt; 50 copies/mL Week 48 objective study establish non-inferiority TMC114/r versus lpv/rtv term virologic response Week 48 use non-inferiority margin 12 % . To test hypothesis , two-sided 95 % confidence interval ( CI ) difference response rate TMC114/r lpv/rtv derive : If low bound CI exceed -12 % , non-inferiority conclude . Patients take oral dos 96 week either 800/100mg TMC114/r 1x/day 800/200mg lpv/rtv daily , combination TDF/FTC . ( The 400/100 mg 2x/day dose lpv/rtv use 1x/day use lpv/rtv approve ) .</detailed_description>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patients document HIV1 infection Screening plasma HIV1 RNA &gt; = 5000 copies/mL Patients qualify treatment initiation base investigator 's assessment and/or accord treatment guideline Patients comply protocol requirement General medical condition , investigator 's opinion , interfere assessment completion trial . Presence currently active AIDS defining illness receive treatment primary HIV infection Life expectancy le 6 month Previous current use antiretroviral medication ( ARVs ) treatment HIVinfection hepatitis B infection antiHIV activity Female patient pregnant breastfeeding , childbearing potential without use effective nonhormonal birth control method willing continue practice birth control method least 30 day end treatment period patient grade 3 4 laboratory abnormality define DAIDS grading , calculate creatinine clearance ( CLCr ) &lt; 70 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Anti-Retroviral agent</keyword>
	<keyword>HIV-1</keyword>
	<keyword>TMC114/r</keyword>
	<keyword>Treatment naïve patient</keyword>
</DOC>